News, reviews and podcasts from annual scientific meetings and symposiums around the world.
AACR 2024: PARP1-selective inhibitor demonstrates early efficacy in breast cancers with DNA repair defects
The first-in-class PARP1-selective inhibitor saruparib demonstrated encouraging early efficacy and a favourable safety profile in…